CLB up +1.80% percent right now. $CLB High is at 139.66 and

New Post Public Reply Private Reply Replies (0) Message Board
Lucky Jimmy
CLB up +1.80% percent right now. $CLB High is at 139.66 and the Low 135.90 with current volume of 436,000.

Recent News posted below.

CLB Core Laboratories N.V. Recent Headline News

Core Laboratories Has Returned 9.4% Since SmarTrend Recommendation (CLB)
Comtex SmarTrend(R) - Wed Nov 05, 5:26PM CST
SmarTrend identified a Downtrend for Core Laboratories (NYSE:CLB) on September 26th, 2014 at $147.44. In approximately 1 month, Core Laboratories has returned 9.36% as of today's recent price of $133.63.
CLB: 138.89 (+2.45)

3 Value Stocks Near 52-Week Lows Worth Buying
Sean Williams, The Motley Fool - Motley Fool - Fri Oct 31, 6:45AM CDT
Just as we often examine companies that may be rising past their fair values, we can also find companies trading at what may be bargain prices. While many investors would rather have nothing to do with stocks wallowing at 52-week lows, I think it...
CVX: 118.80 (+0.27), CLB: 138.89 (+2.45), AEG: 8.19 (+0.05)

Sale of Assets, Acquisition, Suppliers Recognition, and Quarterly Earnings - Research Reports on Chesapeake, Phillips 66, Newmont, EQT and Core
PR Newswire - Tue Oct 28, 8:20AM CDT
Today, Analysts Review released its research reports regarding Chesapeake Energy Corporation (NYSE: CHK), Phillips 66 (NYSE: PSX), Newmont Mining Corporation (NYSE: NEM), EQT Corporation (NYSE: EQT) and Core Laboratories NV (NYSE: CLB). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7492-100free.
EQT: 98.64 (-1.11), PSX: 74.70 (-0.72), CHK: 23.41 (+0.65), NEM: 19.19 (+0.99), SWN: 36.50 (+0.95), CLB: 138.89 (+2.45)

Upgrade Alert for Core Laboratories (CLB)
Comtex SmarTrend(R) - Mon Oct 27, 6:58AM CDT
Core Laboratories (NYSE:CLB) was upgraded from Neutral to Overweight at HSBC today. The stock closed yesterday at $128.97 on volume of 973,000 shares, above average daily volume of 501,000. Core Laboratories N.V. provides reservoir description, production enhancement, and reservoir management services. The Company's customers include major, national, and independent oil and gas producers. Core also manufactures and sells petroleum reservoir rock and fluid analysis instrumentation and other integrated systems.
CLB: 138.89 (+2.45)

Core Laboratories Beats Q3 Earnings, Falls on Guidance Cut - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 24, 12:10PM CDT
Core Laboratories N.V. (CLB) reported third-quarter 2014 adjusted diluted earnings of $1.53 per share, beating the Zacks Consensus Estimate by 2 cents.
CJES: 19.14 (+1.13), NOA: 5.39 (+0.19), CLB: 138.89 (+2.45), EXLP: 27.43 (+0.56)

Core Laboratories Shares Down 13.8% Since SmarTrend's Sell Call (CLB)
Comtex SmarTrend(R) - Fri Oct 24, 9:28AM CDT
SmarTrend identified a Downtrend for Core Laboratories (NYSE:CLB) on September 26th, 2014 at $147.44. In approximately 4 weeks, Core Laboratories has returned 13.79% as of today's recent price of $127.11.
CLB: 138.89 (+2.45)

Core Laboratories (CLB) in Focus: Stock Tumbles 8.19% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Oct 24, 7:59AM CDT
Core Laboratories saw a big move last session, as the company’s shares fell by over 8% continuing the recent downtrend for CLB, as the stock is now down over 13%
NOA: 5.39 (+0.19), CLB: 138.89 (+2.45), EXLP: 27.43 (+0.56)

NYSE stocks posting largest percentage decreases
AP - Thu Oct 23, 5:03PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on New York Stock Exchange at the close of trading:
ESI: 10.14 (+0.12), JONE: 13.54 (+1.71), DDD: 34.47 (-0.44), OCN: 21.17 (-0.24), SKX: 57.60 (-0.11), CAB: 49.46 (-0.24), DRL: 5.50 (+0.57), WTI: 9.31 (+0.70), VOC: 8.67 (+0.18), CLB: 138.89 (+2.45), TUP: 63.54 (-0.44), W: 26.01 (+0.31), GDP: 8.98 (+1.51), SFY: 7.45 (+0.31), SGY: 23.76 (+1.70), UFI: 28.19 (-0.30)

Core Laboratories N.V. Earnings Trump Oil Price Plunge to Hit Record High
Matt DiLallo, The Motley Fool - Motley Fool - Wed Oct 22, 9:37PM CDT
Despite the bear market in oil prices, Core Laboratories N.V. delivered the most profitable quarter in its history, as earnings even topped its own guidance . The company reported third-quarter net income of $67.9 million, or $1.53 per share,...
CLB: 138.89 (+2.45)

Core Laboratories beats 3Q earnings expectations
Automated Insights - Wed Oct 22, 6:31PM CDT
THE NETHERLANDS, Netherlands (AP) _ Core Laboratories NV (CLB) on Wednesday reported third-quarter profit of $66.5 million.
CLB: 138.89 (+2.45)

CLB Q3 2014: New Technology Drives Most Profitable Quarter Ever; All-Time Quarterly Highs For EPS And Net Income; Company Returns Over $107 Million To Shareholders In Quarter
PR Newswire - Wed Oct 22, 6:25PM CDT
In the third quarter of 2014, Core Laboratories N.V. (NYSE: "CLB US" and Euronext Amsterdam: "CLB NA" posted the most profitable quarter in Company history. The record results were driven primarily by new, or recently introduced, technology and related services by Core's Reservoir Description and Production Enhancement operations, in addition to Reservoir Management operations' most profitable third quarter ever. The Company posted all-time quarterly records for earnings per diluted share ("EPS" and net income. Core's third quarter year-over-year EPS increased 13% to $1.53, excluding items referenced in the non-GAAP reconciliations. Third quarter net income increased 9% to $67,900,000, ex-items, from the year-earlier period, while operating income, ex-items, increased 7% to $91,000,000 from the same year-ago quarter. Revenue for the third quarter of 2014 increased to $276,100,000, 3.2% sequentially and 1% over the third quarter of 2013. Operating margins increased sequentially by 190 basis points while year-over-year margins increased 170 basis points to an all-time quarterly high of 33%, ex-items.
CLB: 138.89 (+2.45)

How Badly Will Falling Oil Prices Hurt Core Laboratories N.V. Earnings?
Matt DiLallo, The Motley Fool - Motley Fool - Mon Oct 20, 12:31PM CDT
Oil prices have taken a beating over the past few months, dragging Core Laboratories N.V. stock down along with them. CLB data by YCharts Needless to say, the bear market in oil will likely have an impact when Core Labs reports third...
CLB: 138.89 (+2.45)

Core Lab Announces Q4 2014 Quarterly Dividend
PR Newswire - Mon Oct 06, 4:16PM CDT
The Board of Supervisory Directors of Core Laboratories N.V. (NYSE: "CLB US" and Euronext Amsterdam: "CLB NA" has announced a cash dividend of $0.50 per share of common stock payable in the fourth quarter of 2014. This fourth quarter dividend means a total payout of $2.00 per share of common stock resulting from the four dividends declared and paid during the year 2014. The quarterly $0.50 per share cash dividend will be payable on 25 November 2014 to shareholders of record on 17 October 2014. Dutch withholding tax will be deducted from the dividend at a rate of 15%.
CLB: 138.89 (+2.45)

3 Energy Stocks Tempting Warren Buffett to Buy
Tyler Crowe, The Motley Fool - Motley Fool - Sat Oct 04, 3:29PM CDT
Want to know how to build wealth, following the moves of this guy is a great place to start If you want to build wealth over the long term, quite possibly the best way to do so is to follow the Tao of Warren Buffett: Buy great companies at a...
OII: 71.33 (+1.43), HP: 86.70 (+0.98), CLB: 138.89 (+2.45)

The Next Blue Chip Stocks: Core Laboratories NV
Tyler Crowe, The Motley Fool - Motley Fool - Thu Sep 25, 10:06AM CDT
Source: Core Laboratories When you hear the term blue chip stock, what comes to mind? I'm assuming it's the big companies that we hear about every day, like Coca-Cola , ExxonMobil , or Wal-Mart and not an energy company like Core Laboratories ...
CLB: 138.89 (+2.45)

'Mad Money' Lightning Round: B&G Foods Has Yield but No Growth
at The Street - Wed Sep 24, 5:00AM CDT
Cramer is taking a wait-and-see attitude on Core Labs, HollyFrontier and Dean Foods and prefers Hain Celestial and WhiteWave over SunOpta.
WWAV: 36.93 (-0.53), HAIN: 107.68 (-0.16), BGS: 29.25 (-0.05), STKL: 13.81 (-0.22), HFC: 44.63 (+0.83), DNR: 11.76 (+0.43), DF: 14.42 (+0.16), PCLN: 1,094.61 (-3.14), CLB: 138.89 (+2.45)

Jim Cramer's 'Mad Money' Recap: Why You Must Stay the Course
at The Street - Tue Sep 23, 7:18PM CDT
You have to be ready to seize the opportunities that are being created by a declining market, Cramer advises.
MWE: 70.98 (+2.98), WU: 17.88 (-0.07), WMT: 78.77 (+0.96), STKL: 13.81 (-0.22), HFC: 44.63 (+0.83), CLB: 138.89 (+2.45), PCLN: 1,094.61 (-3.14), WWAV: 36.93 (-0.53), AGN: 196.00 (-1.40), HAIN: 107.68 (-0.16), MGI: 8.41 (-0.02), AZO: 562.23 (-3.82), BGS: 29.25 (-0.05), DF: 14.42 (+0.16), DNR: 11.76 (+0.43), AAPL: 109.01 (+0.31), XOOM: 14.70 (+0.18)

Is Core Laboratories N.V. a Buy After Its 22% Crash in 2014?
Daniel Miller, The Motley Fool - Motley Fool - Tue Sep 23, 9:32AM CDT
Core Laboratories can be a difficult company to evaluate and understand. However, put simply, Core Laboratories' business is helping oil companies better understand their reservoirs, which enables their clients to produce more, thus squeezing as...
CLB: 138.89 (+2.45)

Core Laboratories' Third Quarter 2014 Webcast at 7:30 a.m. CDT / 2:30 p.m. CEST on October 23, 2014
PR Newswire - Mon Sep 22, 3:50PM CDT
Core Laboratories (NYSE: "CLB US" and NYSE Euronext: "CLB NA" will broadcast its third quarter 2014 conference call over the Internet at 7:30 a.m. CDT / 2:30 p.m. CEST on October 23, 2014.
CLB: 138.89 (+2.45)
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Surfing Dogs Ride Waves, Support Orphan Pets

Updated Category News Views 2

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

Continue Reading
PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

Updated Category News Views 4

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

Continue Reading
First-Time Homeowners: Unseen Pitfalls of Insurance

Updated Category News Views 0

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

Continue Reading
GORGIE Unleashes Berry Burst: Target's New Drink Star

Updated Category News Views 2

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

Continue Reading
Tam-Peli Steps Up in SCLC Battle: Trial Insights

Updated Category News Views 5

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Continue Reading
Trial Disappointment: No Significant Gains in NSCLC

Updated Category News Views 7

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Continue Reading
PwC US and India Unite for Global Consultancy Powerhouse

Updated Category News Views 6

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Continue Reading
Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Updated Category News Views 0

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Continue Reading
Ris-Rez May Set New Standard in Relapsed SCLC

Updated Category News Views 4

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

Continue Reading
MRI Surveillance Gains Ground in Lung Cancer Care

Updated Category News Views 3

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

Continue Reading

Top 5 Most Recently Viewed Articles

Cenovus Energy Expands Portfolio with Major Share Acquisition

Updated Category News Views 184

Cenovus Energy Acquires Significant Stake in MEG Energy Cenovus Energy Inc. (TSX: CVE) has recently made a strategic move to acquire 21,723,540 common shares of MEG Energy Corp. ("MEG"), amounting to 8.5% of the total shares outstanding. This acquisition positions Cenovus as a notable shareholder in MEG, reflecting the company’s commitment to growth within the energy...

Continue Reading
Arthur J. Gallagher & Co. Prepares for Q4 2024 Earnings Report

Updated Category News Views 288

Arthur J. Gallagher & Co. Prepares for Q4 2024 Earnings Release Arthur J. Gallagher & Co. (NYSE: AJG) is set to announce its fourth quarter 2024 earnings following the market close on the last day of January 2025. This eagerly awaited financial update will provide insights into the company's performance and strategic direction as it continues to thrive in the dynamic...

Continue Reading
KKR Enhances Tender Offer Strategy for FUJI SOFT Shares

Updated Category News Views 72

KKR Revamps Tender Offer Strategy for FUJI SOFT Shares KKR, a leading global investment firm, has recently made an important change to its tender offer for FUJI SOFT INCORPORATED's common shares. This strategic update appears to provide shareholders with new options and greater flexibility in the tendering process. Decoding the Amendment Statement Alongside the tender...

Continue Reading
TC Transcontinental Sells Industrial Packaging Division

Updated Category News Views 178

TC Transcontinental Makes Strategic Move in Packaging Sector TC Transcontinental has announced an important step in its growth strategy by selling its industrial packaging operations to Hood Packaging Corporation. This significant transaction is valued at US$95 million, which translates to approximately C$132 million, subject to adjustments related to working capital....

Continue Reading
Investing in Wingstop: A Journey Over the Last Five Years

Updated Category News Views 116

Investing in Wingstop: A Journey Over the Last Five Years Wingstop (NASDAQ: WING) has demonstrated impressive growth over the past five years, exceeding market expectations with an annualized return of 34.38%. The company now boasts a market capitalization of $11.69 billion, highlighting its strong performance in the fast-casual dining sector. Your Investment in WING:...

Continue Reading